



Fax completed form to: (855) 840-1678  
 If this is an URGENT request, please call (800) 882-4462  
 (800.88.CIGNA)

# Polivy (polatuzumab vedotin-piiq)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:		* Date of Birth:
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
<b>Urgency:</b> <input type="checkbox"/> Standard <span style="margin-left: 200px;"><input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)</span>					
<b>Medication requested:</b>			ICD10:		
<input type="checkbox"/> Polivy 30mg vial			<input type="checkbox"/> Polivy 140mg vial		
Directions for use:		Quantity:	Duration of therapy:		
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? <span style="float: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No</span>					
<b>Where will this medication be obtained?</b> <input type="checkbox"/> Accredo Specialty Pharmacy** <span style="margin-left: 300px;"><input type="checkbox"/> Retail pharmacy</span> <input type="checkbox"/> Prescriber's office stock (billing on a medical claim form) <span style="margin-left: 200px;"><input type="checkbox"/> Home Health / Home Infusion vendor</span> <input type="checkbox"/> Other (please specify): <span style="margin-left: 200px;">**Cigna's nationally preferred specialty pharmacy</span>					
<i>**Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822   NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557</i>					
<b>Facility and/or doctor dispensing and administering medication:</b> Facility Name: <span style="margin-left: 150px;">State:</span> <span style="margin-left: 150px;">Tax ID#:</span> Address (City, State, Zip Code):					
<b>Is the patient a candidate for home infusion?</b> <span style="float: right;">Yes <input type="checkbox"/> No <input type="checkbox"/></span> <b>Does the physician have an in-office infusion site?</b> <span style="float: right;">Yes <input type="checkbox"/> No <input type="checkbox"/></span>					
<b>Diagnosis related to use:</b> <input type="checkbox"/> AIDS-related B-cell lymphomas <input type="checkbox"/> diffuse large B-cell lymphoma (DLBCL) <input type="checkbox"/> diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) <input type="checkbox"/> follicular lymphoma (FL) <input type="checkbox"/> high-grade B-cell lymphoma <input type="checkbox"/> histologic transformation of nodal marginal zone lymphoma to diffuse large B-cell lymphoma <input type="checkbox"/> mantle cell lymphoma (MCL) <input type="checkbox"/> post-transplant lymphoproliferative disease (PTLD) <input type="checkbox"/> other (please specify):					
<b>Clinical Information:</b>  Will this medication be taken in combination with other chemotherapy agents? <span style="float: right;">Yes <input type="checkbox"/> No <input type="checkbox"/></span> (if yes) Which of the following best describes the other agents to be taken in combination with this medication? <input type="checkbox"/> With bendamustine (Belrapzo, Bendeka, Treanda or Vivimusta) and/or a rituximab product (Riabni, Rituxan, Ruxience, or Truxima) <input type="checkbox"/> With a rituximab product (Riabni, Rituxan, Ruxience, or Truxima), cyclophosphamide, doxorubicin (Adriamycin) and prednisone (R-CHP) <input type="checkbox"/> Other					

(if in combo w/bendamustine and/or rituximab) Has your patient received at least 2 prior therapies for this diagnosis?  Yes  No  
(if DLBCL and in combo w/bendamustine and/or rituximab) Does your patient have relapsed or refractory disease?  Yes  No  
(if FL and in combo w/bendamustine and/or rituximab) Does your patient have grade 1 or grade 2 disease?  Yes  No  
(if DLBCL, NOS in combo w/R-CHP) Has the patient received any type of treatment for this diagnosis before?  Yes  No  
(if high-grade B-cell lymphoma in combo w/R-CHP) Does the patient have an IPI score of 2 or greater?  Yes  No

**Additional Pertinent Information:** *(including disease stage, prior therapy, performance status, and names/doses/admin schedule of any agents to be used concurrently):*

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**Save Time! Submit Online at: [www.covermy meds.com/main/prior-authorization-forms/cigna/](http://www.covermy meds.com/main/prior-authorization-forms/cigna/) or via SureScripts in your EHR.**

*Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at [cigna.com](http://cigna.com).*

V010124  
"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005